HC Wainwright Reiterates “Buy” Rating for Monopar Therapeutics (NASDAQ:MNPR)

Monopar Therapeutics (NASDAQ:MNPR)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $40.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 9.86% from the company’s current price.

Separately, Piper Sandler reiterated an “overweight” rating and issued a $76.00 target price on shares of Monopar Therapeutics in a report on Wednesday, March 19th.

Monopar Therapeutics Stock Down 9.7 %

NASDAQ MNPR opened at $36.41 on Tuesday. The business’s fifty day simple moving average is $38.48 and its 200-day simple moving average is $24.33. The firm has a market cap of $222.17 million, a PE ratio of -18.48 and a beta of 1.18. Monopar Therapeutics has a 52 week low of $1.72 and a 52 week high of $54.30.

Hedge Funds Weigh In On Monopar Therapeutics

A number of hedge funds have recently made changes to their positions in MNPR. Point72 Asset Management L.P. purchased a new stake in shares of Monopar Therapeutics in the 4th quarter valued at $3,694,000. Janus Henderson Group PLC purchased a new stake in Monopar Therapeutics during the fourth quarter worth about $23,435,000. JPMorgan Chase & Co. acquired a new stake in Monopar Therapeutics during the 4th quarter worth approximately $45,000. Geode Capital Management LLC increased its position in shares of Monopar Therapeutics by 174.4% during the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock worth $849,000 after acquiring an additional 24,530 shares during the period. Finally, RA Capital Management L.P. acquired a new stake in shares of Monopar Therapeutics in the fourth quarter valued at $11,247,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.